IP Library › Assignment 066643/0549
Patent Assignment
Reel/Frame 066643/0549

Assignment of Assignor's Interest

Recorded: 2024-02-21 Pages: 30
Assignor
BELLICUM PHARMACEUTICALS, INC.
Executed: 2023-11-21
Assignee
BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
210 WEST 7TH STREET, AUSTIN, TEXAS, 78701
Covered Properties (78)
Modified Dendritic Cells Having Enhanced Survival and Immunogenicity and Related Compositions and Methods
Method for Treating Solid Tumors
Modified Caspase Polypeptides and Uses Thereof
Methods for Controlling T Cell Proliferation
Methods for Inducing Partial Apoptosis Using Caspase Polypeptides
Methods for Activating T Cells Using an Inducible Chimeric Polypeptide
Caspase Polypeptides Having Modified Activity and Uses Thereof
Costimulation of Chimeric Antigen Receptors by MYD88 and CD40 Polypeptides
Methods for Controlled Elimination of Therapeutic Cells
Methods for Controlled Activation or Elimination of Therapeutic Cells
Dual Controls for Therapeutic Cell Activation or Elimination
Methods to Augment or Alter Signal Transduction
Methods for Enhancing and Maintaining Car-T Cell Efficacy
Multimeric Compunds
Natural Killer Cell Products and Methods
Protein-Binding Compounds
T Cells with Suicide Switch
Improved Formulations for Immune Cells
Modified Dendritic Cells Having Enhanced Survival and Immunogenicity and Related Compositions and Methods
Application: 12/301,021 →
Publication: US 2010/0196336
Method for Treating Prostate Cancer Using Modified Antigen-Presenting Cells That Express Inducible CD40 Polypeptides
Application: 13/087,329 →
Publication: US 2011/0287038
Modified Dendritic Cells Having Enhanced Survival and Immunogenicity and Related Compositions and Methods
Patent: 8,486,693 →
Application: 13/622,501 →
Publication: US 2013/0130386
Methods for Treating Prostate Cancer Using Nucleic Acid Compositions
Application: 13/786,652 →
Publication: US 2014/0023647
Modified Caspase Polypeptides and Uses Thereof
Patent: 9,434,935 →
Application: 13/792,135 →
Publication: US 2014/0255360
Methods for Controlling T Cell Proliferation
Patent: 9,944,690 →
Application: 14/210,034 →
Publication: US 2014/0286987
Methods for Inducing Partial Apoptosis Using Caspase Polypeptides
Patent: 9,913,882 →
Application: 14/296,404 →
Publication: US 2016/0151465
MODIFIED T CELL COMPRISING A POLYNUCLEOTIDE ENCODING AN INDUCIBLE STIMULATING MOLECULE COMPRISING MyD88, CD40 AND FKBP12
Application: 14/622,018 →
Publication: US 2016/0046700
Caspase Polypeptides Having Modified Activity and Uses Thereof
Application: 14/640,553 →
Publication: US 2015/0328292
Costimulation of Chimeric Antigen Receptors by MYD88 and CD40 Polypeptides
Application: 14/842,710 →
Publication: US 2016/0058857
Methods for Controlled Elimination of Therapeutic Cells
Application: 14/968,737 →
Publication: US 2016/0166613
Methods for Controlled Activation or Elimination of Therapeutic Cells
Application: 14/968,853 →
Publication: US 2016/0175359
Modified Caspase Polypeptides and Uses Thereof
Patent: 9,932,572 →
Application: 15/224,441 →
Publication: US 2017/0015987
Dual Controls for Therapeutic Cell Activation or Elimination
Application: 15/377,776 →
Publication: US 2017/0166877
Methods for Inducing Partial Apoptosis Using Caspase Polypeptides
Application: 15/888,948 →
Publication: US 2018/0243384
Modified Caspase Polypeptides and Uses Thereof
Application: 15/901,556 →
Publication: US 2018/0251746
Methods for Controlling T Cell Proliferation
Application: 15/910,380 →
Publication: US 2018/0265566
Methods to Augment or Alter Signal Transduction
Application: 16/611,772 →
Publication: US 2021/0147507
Methods for Inducing Partial Apoptosis Using Caspase Polypeptides
Application: 16/734,104 →
Publication: US 2020/0230216
Methods for Enhancing and Maintaining Car-T Cell Efficacy
Application: 16/770,019 →
Publication: US 2020/0347148
Costimulation of Chimeric Antigen Receptors by MYD88 and CD40 Polypeptides
Application: 16/788,062 →
Publication: US 2020/0237886
Multimeric piperidine derivatives
Application: 16/955,693 →
Publication: US 2020/0308144
Natural Killer Cell Products and Methods
Application: 17/053,275 →
Publication: US 2021/0107966
Costimulation of Chimeric Antigen Receptors by MYD88 and CD40 Polypeptides
Application: 17/114,398 →
Publication: US 2021/0346477
Methods for Activating T Cells Using an Inducible Chimeric Polypeptide
Application: 17/176,841 →
Publication: US 2022/0025024
Dual Controls for Therapeutic Cell Activation or Elimination
Application: 17/219,116 →
Publication: US 2023/0065562
T Cells with Suicide Switch
Application: 17/288,845 →
Publication: US 2022/0002674
Methods for Controlled Elimination of Therapeutic Cells
Application: 17/343,071 →
Publication: US 2022/0125837
Methods for Controlled Activation or Elimination of Therapeutic Cells
Application: 17/353,587 →
Publication: US 2022/0152100
Improved Formulations for Immune Cells
Application: 17/632,118 →
Publication: US 2022/0273717
Dual Controls for Therapeutic Cell Activation or Elimination
Application: 18/471,761 →
Publication: US 2024/0368574
Modified Dendritic Cells Having Enhanced Survival and Immunogenicity and Related Compositions and Methods
Application: 60/803,025 →
Method for Treating Solid Tumors
Application: 61/325,127 →
Method for Treating Solid Tumors
Application: 61/351,760 →
Method for Treating Solid Tumors
Application: 61/442,582 →
Method for Controlling T Cell Proliferation
Application: 61/783,445 →
Methods for Inducing Partial Apoptosis Using Modified Caspase Polypeptides
Application: 61/831,428 →
Methods for Activating T Cells Using an Inducible Chimeric Polypeptide
Application: 61/940,347 →
Caspase Polypeptides Having Modified Activity and Uses Thereof
Application: 61/949,787 →
Methods for Inducing Partial Apoptosis Using Modified Caspase Polypeptides
Application: 61/949,847 →
Methods for Activating T Cells Using an Inducible Chimeric Polypeptide
Application: 61/952,839 →
Caspase Polypeptides Having Modified Activity and Uses Thereof
Application: 62/007,902 →
Costimulation of Chimeric Antigen Receptors by MYD88 and CD40 Polypeptides
Application: 62/044,885 →
Caspase Polypeptides Having Modified Activity and Uses Thereof
Application: 62/047,870 →
Methods for Activating T Cells Using an Inducible Chimeric Polypeptide
Application: 62/047,875 →
Methods for Controlled Elimination of Therapeutic Cells
Application: 62/092,149 →
Costimulation of Chimeric Antigen Receptors by MYD88 and CD40 Polypeptides
Application: 62/115,735 →
Costimulation of Chimeric Antigen Receptors by MYD88 and CD40 Polypeptides
Application: 62/143,503 →
Methods for Controlled Activation or Elimination of Therapeutic Cells
Application: 62/148,386 →
Dual Controls for Therapeutic Cell Activation or Elimination
Application: 62/267,277 →
Methods to Augment or Alter Signal Transduction
Application: 62/503,565 →
Methods for Enhancing and Maintaining Car T-Cell Efficacy
Application: 62/596,744 →
Multimeric Compounds
Application: 62/608,552 →
Natural Killer Cell Products and Methods
Application: 62/668,223 →
Protein-Binding Compounds
Application: 62/744,813 →
T Cells with Suicide Switch
Application: 62/753,688 →
Natural Killer Cell Products and Methods
Application: 62/756,442 →
Natural Killer Cell Products and Methods
Application: 62/816,799 →
Formulations for Immune Cells
Application: 62/885,747 →
Selective Apoptosis-Inducing Methods
Application: 63/386,728 →
Related Assignments (21)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Nov 18, 2013
From: SPENCER, DAVID; CHANG, WEI-CHUN
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 031624/0291 →
Assignment of Assignor's Interest Aug 4, 2014
From: SLAWIN, KEVIN; SPENCER, DAVID; FOSTER, AARON EDWARD
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 033454/0247 →
Assignment of Assignor's Interest Aug 12, 2014
From: SPENCER, DAVID; FOSTER, AARON EDWARD
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 033519/0247 →
Assignment of Assignor's Interest Feb 25, 2015
From: SLAWIN, KEVIN
To: BELLICUM PHARMACEUTICALS, INC
Reel/Frame 035030/0314 →
Assignment of Assignor's Interest Feb 25, 2015
From: SPENCER, DAVID; LAPTEVA, NATALIA
To: BAYLOR COLLEGE OF MEDICINE
Reel/Frame 035030/0269 →
Assignment of Assignor's Interest Feb 25, 2015
From: SLAWIN, KEVIN
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 035026/0972 →
Assignment of Assignor's Interest Jun 23, 2015
From: SPENCER, DAVID; CHANG, WEI-CHUN; SLAWIN, KEVIN
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 035954/0161 →
Assignment of Assignor's Interest Oct 22, 2015
From: SPENCER, DAVID; FOSTER, AARON EDWARD; SLAWIN, KEVIN
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 036857/0666 →
Assignment of Assignor's Interest Jan 15, 2016
From: FOSTER, AARON EDWARD; SPENCER, DAVID; COLLINSON-PAUTZ, MATTHEW ROBERT; SLAWIN, KEVIN
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 037503/0720 →
Assignment of Assignor's Interest Feb 18, 2016
From: SPENCER, DAVID M.; FOSTER, AARON EDWARD; BAYLE, JOSEPH HENRI; SLAWIN, KEVIN M.
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 037766/0669 →
Assignment of Assignor's Interest Mar 29, 2016
From: SPENCER, DAVID M.; BAYLE, JOSEPH HENRI; FOSTER, AARON EDWARD; SLAWIN, KEVIN M.
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 038128/0830 →
Assignment of Assignor's Interest Aug 3, 2016
From: SLAWIN, KEVIN
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 039335/0833 →
Assignment of Assignor's Interest Oct 6, 2016
From: SPENCER, DAVID; CHANG, WEI-CHUN
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 039961/0691 →
Assignment of Assignor's Interest Dec 22, 2016
From: BAYLE, JOSEPH HENRI; DUONG, MYLINH THI; COLLINSON-PAUTZ, MATTHEW ROBERT; FOSTER, AARON EDWARD
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 040752/0892 →
Assignment of Assignor's Interest Jun 28, 2018
From: BAYLE, JOSEPH HENRI; CHANG, WEI-CHUN; FOSTER, AARON EDWARD; SPENCER, DAVID MICHAEL
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 046231/0611 →
Assignment of Assignor's Interest Mar 13, 2020
From: BAYLE, JOSEPH HENRI; SZYMANSKI, SLAWOMIR; COLLINSON-PAUTZ, MATTHEW ROBERT; TOLER, STEVEN MARK
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 052110/0266 →
Security Interest Apr 1, 2020
From: BELLICUM PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 052284/0113 →
Assignment of Assignor's Interest Jun 9, 2020
From: BAYLE, JOSEPH HENRI; SZYMANSKI, SLAWOMIR; COLLINSON-PAUTZ, MATTHEW ROBERT; TOLER, STEVEN MARK
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 052883/0001 →
Assignment of Assignor's Interest Jul 9, 2020
From: TOLER, STEVEN; SZYMANSKI, SLAWOMIR
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 053168/0594 →
Release of Security Interest Nov 3, 2020
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 054295/0946 →
Assignment of Assignor's Interest Nov 18, 2020
From: BAEZ, OMAR; BLASS, DEVIN
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 054402/0780 →